Modulation of TH action has been proposed for nonalcoholic fatty liver disease treatment (Kowalik et al., 2018; Zhao et al., 2022), and our data may assist in the design of a time-of-day-dependent drug regime for this approach (Marjot et al., 2022). The gene discussed is TH; the disease is metabolic dysfunction-associated steatotic liver disease.